697 related articles for article (PubMed ID: 18388116)
1. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Han SY; Kim CH; Kim HS; Jee YH; Song HK; Lee MH; Han KH; Kim HK; Kang YS; Han JY; Kim YS; Cha DR
J Am Soc Nephrol; 2006 May; 17(5):1362-72. PubMed ID: 16571782
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
[TBL] [Abstract][Full Text] [Related]
5. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity.
Rudofsky G; Reismann P; Grafe IA; Konrade I; Djuric Z; Tafel J; Buchbinder S; Zorn M; Humpert PM; Hamann A; Morcos M; Nawroth PP; Bierhaus A
Horm Metab Res; 2007 Sep; 39(9):665-71. PubMed ID: 17846974
[TBL] [Abstract][Full Text] [Related]
6. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
[TBL] [Abstract][Full Text] [Related]
7. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation.
Hagiwara S; Makita Y; Gu L; Tanimoto M; Zhang M; Nakamura S; Kaneko S; Itoh T; Gohda T; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Mar; 21(3):605-15. PubMed ID: 16282336
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy.
Mezzano S; Aros C; Droguett A; Burgos ME; Ardiles L; Flores C; Schneider H; Ruiz-Ortega M; Egido J
Nephrol Dial Transplant; 2004 Oct; 19(10):2505-12. PubMed ID: 15280531
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway.
Zhang HL; Xu M; Wei C; Qin AP; Liu CF; Hong LZ; Zhao XY; Liu J; Qin ZH
Neuroscience; 2011 Mar; 176():381-95. PubMed ID: 21185913
[TBL] [Abstract][Full Text] [Related]
10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y
J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.
Remels AH; Langen RC; Gosker HR; Russell AP; Spaapen F; Voncken JW; Schrauwen P; Schols AM
Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E174-83. PubMed ID: 19417127
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Ohga S; Shikata K; Yozai K; Okada S; Ogawa D; Usui H; Wada J; Shikata Y; Makino H
Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1141-50. PubMed ID: 17190910
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.
Konturek PC; Brzozowski T; Kania J; Kukharsky V; Bazela K; Kwiecien S; Harsch I; Konturek SJ; Hahn EG
Scand J Gastroenterol; 2003 May; 38(5):468-76. PubMed ID: 12795455
[TBL] [Abstract][Full Text] [Related]
18. Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats.
Chen L; Zhang J; Zhang Y; Wang Y; Wang B
Inflamm Res; 2008 May; 57(5):199-204. PubMed ID: 18465086
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-gamma agonists attenuate angiotensin II-induced collagen type I expression in adventitial fibroblasts.
Zhang J; Fang NY; Gao PJ; Wu LY; Han WQ; Guo SJ; Shen WL; Zhu DL
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):72-7. PubMed ID: 18047631
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy.
Wang JJ; Zhang SX; Mott R; Chen Y; Knapp RR; Cao W; Ma JX
Am J Physiol Renal Physiol; 2008 May; 294(5):F1166-73. PubMed ID: 18322021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
